Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class

Urologic Clinics of North America

Volumn 34, Issue 4, 2007, Pages 507-515

  Carson III, Culley C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVANAFIL; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

COLOR VISION; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPEPSIA; ERECTILE DYSFUNCTION; FLU LIKE SYNDROME; FLUSHING; FOOD DRUG INTERACTION; GASTROESOPHAGEAL REFLUX; GRAPEFRUIT JUICE; HUMAN; LIPID DIET; MYALGIA; NOSE CONGESTION; PATIENT SATISFACTION; PRIORITY JOURNAL; QT INTERVAL; REVIEW; RHINITIS; RHINOPHARYNGITIS; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SIDE EFFECT; SINUS CONGESTION; SINUSITIS; THERAPY EFFECT; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE; VISION;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; HUMANS; MALE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS;

EID: 35648976611     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.08.013     Document Type: Review

References (61)

1. Carson C.C., and Lue T.F. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 96 3 (2005) 257-280
2. Bella A.J., Deyoung L.X., Al-Numi M., et al. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 52 4 (2007) 990-1005
3. Lue T.F. Erectile dysfunction. N Engl J Med 342 24 (2000) 1802-1813
4. Butcher R.W., and Sutherland E.W. Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J Biol Chem 237 (1962) 1244-1250
5. Sutherland E.W., and Rall T.W. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem 232 2 (1958) 1077-1091
6. Corbin J.D. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res 16 Suppl 1 (2004) S4-S7
7. Francis S.H., Turko I.V., and Corbin J.D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65 (2001) 1-52
8. Seftel A.D. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol 27 4 Suppl 1 (2004) I14-I19
9. Carson C.C., Rajfer J., Eardley I., et al. The efficacy and safety of tadalafil: an update. BJU Int 93 9 (2004) 1276-1281
10. Gresser U., and Gleiter C.H. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res 7 10 (2002) 435-446
11. Hellstrom W.J., Overstreet J.W., Yu A., et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 170 3 (2003) 887-891
12. Corbin J.D., and Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56 6 (2002) 453-459
13. Padma-Nathan H., and Giuliano F. Oral drug therapy for erectile dysfunction. Urol Clin North Am 28 2 (2001) 321-334
14. Rajagopalan P., Mazzu A., Xia C., et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 43 3 (2003) 260-267
15. Corbin J.D., Beasley A., Blount M.A., et al. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int 45 6 (2004) 859-863
16. Brock G.B., McMahon C.G., Chen K.K., et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168 4 Pt 1 (2002) 1332-1336
17. Porst H., Padma-Nathan H., Giuliano F., et al. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology 62 1 (2003) 121-125 [discussion: 125-6]
18. Carson CC S.R., and Orazem J. Sildenafil citrate treatment for erectile dysfunction: rate of adverse events decreases with time. J Urol 167 (2002) 167-179
19. Stief C., Porst H., Saenz De Tejada I., et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 58 3 (2004) 230-239
20. Pfizer. Sildenafil citrate (Viagra) US prescribing information. Available at: http://www.pfizer.com/download/uspi_viagra.pdf. Accessed July 6, 2007.
21. ICOS L. Tadalafil (Cialis) US prescribing information. Available at: http://www.lilly.com/us/cialis-pi.pdf. Accessed July 6, 2007.
22. GSK. Vardenafil hydrochloride (Levitra) US prescribing information. Available at: http://www.univgraph.com/bayer/inserts/levitra.pdf. Accessed July 6, 2007.
23. Kostis J.B., Jackson G., Rosen R., et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am J Cardiol 96 2 (2005) 313-321
24. Carson III C.C. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. Am J Cardiol 96 12B (2005) 37M-41M
25. Sussman D.O. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc 104 3 Suppl 4 (2004) S11-S15
26. Ishikura F., Beppu S., Hamada T., et al. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation 102 20 (2000) 2516-2521
27. Webb D.J., Muirhead G.J., Wulff M., et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 36 1 (2000) 25-31
28. Kloner R.A., Hutter A.M., Emmick J.T., et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 42 10 (2003) 1855-1860
29. Padma-Nathan H., Steers W.D., and Wicker P.A. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 52 6 (1998) 375-379
30. Hellstrom W.J., Gittelman M., Karlin G., et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 23 6 (2002) 763-771
31. Bayer. Vardenafil hydrochloride (Levitra) US prescribing information. Available at: http://www.univgraph.com/bayer/inserts/levitra.pdf. Accessed September 24, 2004.
32. Pfizer. Sildenafil citrate (Viagra). US prescribing information. Available at: http://www.pfizer.com/download/uspi_viagra.pdf. Accessed July 6, 2007.
33. Lilly, ICOS, LLC. Cialis (tadalafil). US prescribing information. Available at: http://pi_lilly.com/us/cialis-pi.pdf. Accessed July 6, 2007.
34. Jetter A., Kinzig-Schippers M., Walchner-Bonjean M., et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther 71 1 (2002) 21-29
35. Leslie S.J., Atkins G., Oliver J.J., et al. No adverse hemodynamic interaction between sildenafil and red wine. Clin Pharmacol Ther 76 4 (2004) 365-370
36. Carson C.C. Long-term use of sildenafil. Expert Opin Pharmacother 4 3 (2003) 397-405
37. Hellstrom W.J., Gittelman M., Karlin G., et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61 4 Suppl 1 (2003) 8-14
38. Carson III C.C. Efficacy and safety of tadalafil in men with severe erectile dysfunction in tertiary care academic centers. Curr Urol Rep 6 6 (2005) 437-438
39. Carson C., Shabsigh R., Segal S., et al. Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. Urology 65 2 (2005) 353-359
40. Saenz de Tejada I., Anglin G., Knight J.R., et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 25 12 (2002) 2159-2164
41. Fonseca V., Seftel A., Denne J., et al. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. Diabetologia 47 11 (2004) 1914-1923
42. Goldstein I., Young J.M., Fischer J., et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 26 3 (2003) 777-783
43. Rendell M.S., Rajfer J., Wicker P.A., et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 281 5 (1999) 421-426
44. Lowentritt B.H., Scardino P.T., Miles B.J., et al. Sildenafil citrate after radical retropubic prostatectomy. J Urol 162 5 (1999) 1614-1617
45. Montorsi F., Nathan H.P., McCullough A., et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol 172 3 (2004) 1036-1041
46. Hong E.K., Lepor H., and McCullough A.R. Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res 11 Suppl 1 (1999) S15-S22
47. Brock G., Nehra A., Lipshultz L.I., et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 170 4 Pt 1 (2003) 1278-1283
48. McCullough A.R. An update on the PDE-5 inhibitors (PDE-5i). J Androl 24 6 Suppl (2003) S52-S58
49. Shabsigh R., Kaufman J.M., Steidle C., et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172 2 (2004) 658-663
50. Sairam K., Kulinskaya E., McNicholas T.A., et al. Sildenafil influences lower urinary tract symptoms. BJU Int 90 9 (2002) 836-839
51. McVary K.T., Monnig W., Camps Jr. J.L., et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177 3 (2007) 1071-1077
52. McVary K.T., Roehrborn C.G., Kaminetsky J.C., et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177 4 (2007) 1401-1407
53. Padma-Nathan H., Stecher V.J., Sweeney M., et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. Urology 62 3 (2003) 400-403
54. Carson III C.C., Hubbard J.S., and Wallen E. Erectile dysfunction and treatment of carcinoma of the prostate. Curr Urol Rep 6 6 (2005) 461-469
55. Bates M.G., Thompson A.A., and Baillie J.K. Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema. Curr Opin Investig Drugs 8 3 (2007) 226-231
56. Krymskaya V.P., and Panettieri Jr. R.A. Phosphodiesterases regulate airway smooth muscle function in health and disease. Curr Top Dev Biol 79 (2007) 61-74
57. Kane L.B., and Klings E.S. Present and future treatment strategies for pulmonary arterial hypertension: focus on phosphodiesterase-5 inhibitors. Treat Respir Med 5 4 (2006) 271-282
58. Reffelmann T., and Kloner R.A. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des 12 27 (2006) 3485-3494
59. Gratzke C., Uckert S., Kedia G., et al. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res 35 1 (2007) 49-54
60. Salem E.A., Kendirci M., and Hellstrom W.J. Udenafil, a long-acting PDE5 inhibitor for erectile dysfunction. Curr Opin Investig Drugs 7 7 (2006) 661-669
61. Bayes M., Rabasseda X., and Prous J.R. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 28 10 (2006) 719-740